217 related articles for article (PubMed ID: 35655709)
21. Mouse pancreatic beta cells express MHC class II and stimulate CD4(+) T cells to proliferate.
Zhao Y; Scott NA; Quah HS; Krishnamurthy B; Bond F; Loudovaris T; Mannering SI; Kay TW; Thomas HE
Eur J Immunol; 2015 Sep; 45(9):2494-503. PubMed ID: 25959978
[TBL] [Abstract][Full Text] [Related]
22. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
23. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination.
Collignon A; Perles-Barbacaru AT; Robert S; Silvy F; Martinez E; Crenon I; Germain S; Garcia S; Viola A; Lombardo D; Mas E; Béraud E
Oncotarget; 2015 Sep; 6(27):23462-79. PubMed ID: 26405163
[TBL] [Abstract][Full Text] [Related]
24. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
Bonehill A; Heirman C; Thielemans K
J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
[TBL] [Abstract][Full Text] [Related]
25. MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
Walter W; Lingnau K; Schmitt E; Loos M; Maeurer MJ
Br J Cancer; 2000 Nov; 83(9):1192-201. PubMed ID: 11027433
[TBL] [Abstract][Full Text] [Related]
26. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers.
Bradley SD; Talukder AH; Lai I; Davis R; Alvarez H; Tiriac H; Zhang M; Chiu Y; Melendez B; Jackson KR; Katailiha A; Sonnemann HM; Li F; Kang Y; Qiao N; Pan BF; Lorenzi PL; Hurd M; Mittendorf EA; Peterson CB; Javle M; Bristow C; Kim M; Tuveson DA; Hawke D; Kopetz S; Wolff RA; Hwu P; Maitra A; Roszik J; Yee C; Lizée G
Nat Commun; 2020 Oct; 11(1):5332. PubMed ID: 33087697
[TBL] [Abstract][Full Text] [Related]
27. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.
Aarntzen EH; De Vries IJ; Lesterhuis WJ; Schuurhuis D; Jacobs JF; Bol K; Schreibelt G; Mus R; De Wilt JH; Haanen JB; Schadendorf D; Croockewit A; Blokx WA; Van Rossum MM; Kwok WW; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2013 Jan; 73(1):19-29. PubMed ID: 23087058
[TBL] [Abstract][Full Text] [Related]
28. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production.
McMenamin C; Holt PG
J Exp Med; 1993 Sep; 178(3):889-99. PubMed ID: 8102390
[TBL] [Abstract][Full Text] [Related]
29. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
30. Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.
Hillman GG; Kallinteris NL; Lu X; Wang Y; Wright JL; Li Y; Wu S; Forman JD; Gulfo JV; Humphreys RE; Xu M
Cancer Treat Rev; 2004 May; 30(3):281-90. PubMed ID: 15059651
[TBL] [Abstract][Full Text] [Related]
31. Schwann cells co-cultured with stimulated T cells and antigen express major histocompatibility complex (MHC) class II determinants without interferon-gamma pretreatment: synergistic effects of interferon-gamma and tumor necrosis factor on MHC class II induction.
Kingston AE; Bergsteinsdottir K; Jessen KR; Van der Meide PH; Colston MJ; Mirsky R
Eur J Immunol; 1989 Jan; 19(1):177-83. PubMed ID: 2493382
[TBL] [Abstract][Full Text] [Related]
32. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.
Accolla RS; Ramia E; Tedeschi A; Forlani G
Front Immunol; 2019; 10():1806. PubMed ID: 31417570
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo.
Xiang J; Moyana T
Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051
[TBL] [Abstract][Full Text] [Related]
34. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
Panchal K; Sahoo RK; Gupta U; Chaurasiya A
Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
[TBL] [Abstract][Full Text] [Related]
35. Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides.
Hsu DH; Paz P; Villaflor G; Rivas A; Mehta-Damani A; Angevin E; Zitvogel L; Le Pecq JB
J Immunother; 2003; 26(5):440-50. PubMed ID: 12973033
[TBL] [Abstract][Full Text] [Related]
36. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
37. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Neuwelt AJ; Kimball AK; Johnson AM; Arnold BW; Bullock BL; Kaspar RE; Kleczko EK; Kwak JW; Wu MH; Heasley LE; Doebele RC; Li HY; Nemenoff RA; Clambey ET
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32312906
[TBL] [Abstract][Full Text] [Related]
38. CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma.
Raj D; Nikolaidi M; Garces I; Lorizio D; Castro NM; Caiafa SG; Moore K; Brown NF; Kocher HM; Duan X; Nelson BH; Lemoine NR; Marshall JF
Clin Cancer Res; 2021 Mar; 27(5):1538-1552. PubMed ID: 33479048
[TBL] [Abstract][Full Text] [Related]
39. Lymphocyte-mediated activation of cultured endothelial cells (EC). CD4+ T cells inhibit EC class II MHC expression despite secreting IFN-gamma and increasing EC class I MHC and intercellular adhesion molecule-1 expression.
Doukas J; Pober JS
J Immunol; 1990 Aug; 145(4):1088-98. PubMed ID: 1974272
[TBL] [Abstract][Full Text] [Related]
40. Existence of MHC class I-restricted alloreactive CD4+ T cells reacting with peptide transporter-deficient cells.
Kobayashi H; Kimura S; Aoki N; Sato K; Celis E; Katagiri M
Immunogenetics; 2001 Oct; 53(8):626-33. PubMed ID: 11797095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]